Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HGS Lymphostat-B Is 1 Of 7 Agents Selected For FDA’s Pilot 2 CMA Program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA has selected Human Genome Sciences’ lupus biologic Lymphostat-B for the continuous marketing application (CMA) Pilot 2 program, HGS announced March 4.

You may also be interested in...



J&J Completes Zarnestra Submission For Leukemia Under Pilot 1 Program

J&J Completes Zarnestra Submission For Leukemia Under Pilot 1 Program

FDA Extends Continuous Marketing Application Pilot 2 Deadline Again

FDA extends continuous marketing application Pilot 2 deadline again. At least eight CDER divisions have chosen INDs for the fast-track pilot program, with eight remaining. Applications will be accepted until Dec. 31

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS002492

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel